XRCC2 (DNA repair protein XRCC2) variants and mutations
XRCC2 (also known as DNA repair protein XRCC2) is a human protein-coding gene encoding a DNA repair protein. It acts with other RAD51 paralogs to assemble and stabilize homologous-recombination repair machinery at DNA double-strand breaks. Biallelic loss-of-function variants can cause Fanconi-anemia-like chromosome-instability disease, while heterozygous cancer-risk associations are less certain. This analysis covers 818 XRCC2 variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes spermatogenic failure 50, Fanconi anemia, and hereditary neoplastic syndrome. Example XRCC2 variants include M1I, M1T, and C2F.
Variant analysis overview
- Gene: XRCC2
- Protein: DNA repair protein XRCC2
- UniProt accession: O43543
- Organism: Homo sapiens
- Variants analyzed: 818
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 590 unspecified-consequence records; 1 stop retained variant; 99 synonymous variants; 2 in-frame insertions; 36 frameshift variants; 10 in-frame deletions; 71 missense variants; 6 stop-gained variants; 1 protein altering variant; 1 splice-region variants; 1 substitution
- Prediction scores: 700 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: spermatogenic failure 50, Fanconi anemia, hereditary neoplastic syndrome, Inherited cancer-predisposing syndrome, cancer, Fanconi anemia complementation group U, myelodysplastic syndrome, acute myeloid leukemia, premature ovarian failure 17, primary ovarian failure, Hereditary breast and ovarian cancer syndrome, male infertility with azoospermia or oligozoospermia due to single gene mutation.
Protein structure and variant hotspots
- Protein features: 1 post-translational modification sites.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable XRCC2 variants
Examples include M1I, M1T, C2F, C2R, C2Y, p.Cys2 Ala4del, S3G, S3N. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs2117014477, ClinGen CA370199651, ClinVar RCV003077201, MetaLR 0.13, MetaSVM -0.87, Uncertain significance, not provided
- M1T (p.Met1Thr), rs1064793295, ClinGen CA16618441, ClinVar RCV002435642, MetaLR 0.11, MetaSVM -0.91, Likely pathogenic, Hereditary cancer-predisposing syndrome
- C2F (p.Cys2Phe), Ensembl rs2117014469
- C2R (p.Cys2Arg), TOPMed rs2098040963, gnomAD rs2098040963, REVEL 0.04, MetaLR 0.11
- C2Y (p.Cys2Tyr), Ensembl rs2117014469
- p.Cys2 Ala4del, gnomAD 7-152676066-AAGGC, CADD 20.50
- S3G (p.Ser3Gly), rs762701579, ClinGen CA4582449, ClinVar RCV000484929, ClinVar RCV000708766, REVEL 0.10, MetaLR 0.11, Conflicting interpretations, Hereditary cancer-predisposing syndrome; XRCC2-related disorder; not provided
- S3N (p.Ser3Asn), ExAC rs775671215, REVEL 0.06, MetaLR 0.13
- S3S (p.Ser3Ser), rs1211283181, gnomAD 7-152676071-A-G, CADD 14.70
- S3T (p.Ser3Thr), gnomAD 7-152676072-C-G, REVEL 0.05, MetaLR 0.13
- S3K (p.Ser3Lys), rs1563035900, gnomAD 7-152676072-C-CT, CADD 33.00
- A4S (p.Ala4Ser), rs1204405661, ClinGen CA370199634, ClinVar RCV001308592, ClinVar RCV003166760, REVEL 0.07, MetaLR 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- A4T (p.Ala4Thr), rs1204405661, ClinGen CA370199632, ClinVar RCV003216344, REVEL 0.07, MetaLR 0.11, Uncertain significance, Hereditary cancer-predisposing syndrome
- A4V (p.Ala4Val), rs2098040951, gnomAD 7-152676062-ATGGA, CADD 31.00
- A4G (p.Ala4Gly), gnomAD 7-152676069-G-GC, CADD 28.30
- F5L (p.Phe5Leu), gnomAD 7-152676065-G-T, REVEL 0.07, MetaLR 0.10
- H6R (p.His6Arg), rs2485915656, ClinGen CA370199617, ClinVar RCV002407863, ClinVar RCV006258838, REVEL 0.04, MetaLR 0.05, Conflicting interpretations, Hereditary cancer-predisposing syndrome; not provided
- H6Y (p.His6Tyr), TOPMed rs1043636944, gnomAD rs1043636944, REVEL 0.07, MetaLR 0.15, Uncertain significance, Hereditary cancer-predisposing syndrome
- p.His6 Ala8delinsPro, gnomAD 7-152676057-GCCCT, CADD 16.90
- H6H (p.His6His), rs2098040949, gnomAD 7-152676062-A-G, CADD 8.74
- R7G (p.Arg7Gly), rs1337184659, ClinGen CA370199613, ClinVar RCV003377782, gnomAD rs1337184659, AlphaMissense 0.14, MetaLR 0.11, Uncertain significance, Hereditary cancer-predisposing syndrome
- R7S (p.Arg7Ser), 1000Genomes rs531499084, ExAC rs531499084, TOPMed rs531499084, gnomAD rs531499084, Likely benign
- R7W (p.Arg7Trp), gnomAD rs1337184659, REVEL 0.21, AlphaMissense 0.14, Uncertain significance
- R7R (p.Arg7Arg), rs531499084, gnomAD 7-152676059-C-T, CADD 13.80
- A8P (p.Ala8Pro), rs2098040942, ClinGen CA370199606, ClinVar RCV004521356, REVEL 0.17, MetaLR 0.14, Uncertain significance, Hereditary cancer-predisposing syndrome
- A8T (p.Ala8Thr), rs2098040942, ClinGen CA370199605, ClinVar RCV001299241, ClinVar RCV004951462, REVEL 0.03, MetaLR 0.11, Conflicting interpretations, Hereditary cancer-predisposing syndrome; not provided
- E9K (p.Glu9Lys), rs1227610646, ClinGen CA370199599, ClinVar RCV002426230, REVEL 0.20, MetaLR 0.21, Uncertain significance, Hereditary cancer-predisposing syndrome
- E9Q (p.Glu9Gln), rs1227610646, ClinGen CA370199600, ClinVar RCV002426235, TOPMed rs1227610646, REVEL 0.18, MetaLR 0.29, Uncertain significance, Hereditary cancer-predisposing syndrome
- E9E (p.Glu9Glu), rs1339516564, gnomAD 7-152676053-C-T, CADD 13.80
- E9V (p.Glu9Val), gnomAD 7-152676054-TCA-T, CADD 32.00
- S10F (p.Ser10Phe), rs2098040936, ClinGen CA370199587, ClinVar RCV001213679, ClinVar RCV003353212, REVEL 0.21, MetaLR 0.20, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- G11R (p.Gly11Arg), rs746259775, ClinGen CA370199586, ClinVar RCV003080077, ClinVar RCV005515499, REVEL 0.31, MetaLR 0.25, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- G11V (p.Gly11Val), rs2485915602, ClinGen CA370199582, ClinVar RCV002454686, Uncertain significance, Hereditary cancer-predisposing syndrome
- G11G (p.Gly11Gly), rs781763823, gnomAD 7-152676047-C-T, CADD 14.40
- T12A (p.Thr12Ala), TOPMed rs2098040934
- T12I (p.Thr12Ile), rs2485915590, ClinGen CA370199576, ClinVar RCV002455183, Uncertain significance, Hereditary cancer-predisposing syndrome
- T12N (p.Thr12Asn), rs2485915590, ClinGen CA370199578, ClinVar RCV002455179, REVEL 0.04, MetaLR 0.14, Uncertain significance, Hereditary cancer-predisposing syndrome
- T12T (p.Thr12Thr), gnomAD 7-152676044-G-A, CADD 11.20
- T12S (p.Thr12Ser), gnomAD 7-152676045-G-C, REVEL 0.08, MetaLR 0.11
- E13D (p.Glu13Asp), rs373877121, ClinGen CA4582444, ClinVar RCV001337487, ClinVar RCV002357175, REVEL 0.04, MetaLR 0.13, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- E13Q (p.Glu13Gln), rs1590140903, ClinGen CA370199574, ClinVar RCV000815635, ClinVar RCV001021184, AlphaMissense 0.13, MetaLR 0.08, Conflicting interpretations, Hereditary cancer-predisposing syndrome; not provided
- E13K (p.Glu13Lys), gnomAD 7-152676043-C-T, REVEL 0.11, MetaLR 0.10
- L14=, rs751479865, NCI-TCGA Cosmic COSV6377, Variant assessed as somatic; low impact., in SPGF50 and POF17
- L14F (p.Leu14Phe), rs1029144797, ClinGen CA16618439, ClinVar RCV000486879, ClinVar RCV002323835, REVEL 0.21, MetaLR 0.44, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- L14H (p.Leu14His), rs757140620, ClinGen CA370199556, ClinVar RCV002000782, ClinVar RCV002331571, REVEL 0.53, MetaLR 0.43, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- L14I (p.Leu14Ile), NCI-TCGA TCGA novel, REVEL 0.16, MetaLR 0.39, Variant assessed as somatic; moderate impact., in SPGF50 and POF17
- L14P (p.Leu14Pro), rs757140620, ClinGen CA4582418, ClinVar RCV001280534, ClinVar RCV001280535, REVEL 0.67, MetaLR 0.42, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- L14V (p.Leu14Val), rs1029144797, ClinGen CA169488184, ClinVar RCV001207039, ClinVar RCV002322014, REVEL 0.18, MetaLR 0.40, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- L14L (p.Leu14Leu), rs751479865, gnomAD 7-152660780-G-A, CADD 10.40
- L15P (p.Leu15Pro), rs2485896936, ClinGen CA370199550, ClinVar RCV002328695, REVEL 0.54, MetaLR 0.40, Uncertain significance, Hereditary cancer-predisposing syndrome
- L15F (p.Leu15Phe), gnomAD 7-152660779-G-A, REVEL 0.04, MetaLR 0.17
- A16P (p.Ala16Pro), rs4987090, ClinGen CA4582415, ClinVar RCV004521369, ESP rs4987090, REVEL 0.26, MetaLR 0.32, Uncertain significance, Hereditary cancer-predisposing syndrome
- A16S (p.Ala16Ser), rs4987090, ClinGen CA4582416, ClinVar RCV001045634, ClinVar RCV002339230, REVEL 0.11, MetaLR 0.13, Conflicting interpretations, not provided; Hereditary cancer-predisposing syndrome
- A16V (p.Ala16Val), ExAC rs752207601, gnomAD rs752207601, REVEL 0.24, MetaLR 0.28
- A16A (p.Ala16Ala), gnomAD 7-152660774-G-T, CADD 9.27
- R17* (p.Arg17Ter), rs750903875, ClinGen CA4582413, NCI-TCGA Cosmic COSV6377, ClinVar RCV000574813, CADD 38.00, Pathogenic
- R17P (p.Arg17Pro), ExAC rs759291002, TOPMed rs759291002, gnomAD rs759291002, MetaLR 0.58, MetaSVM 0.22, Uncertain significance
- R17Q (p.Arg17Gln), rs759291002, ClinGen CA4582412, NCI-TCGA Cosmic COSV6377, ClinVar RCV000480720, REVEL 0.38, MetaLR 0.58, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- R17L (p.Arg17Leu), gnomAD 7-152660772-C-A, REVEL 0.53, MetaLR 0.58
- R17R (p.Arg17Arg), gnomAD 7-152660773-G-T, CADD 10.70
- R17G (p.Arg17Gly), gnomAD 7-152660773-G-C, REVEL 0.52, MetaLR 0.58
- L18F (p.Leu18Phe), ExAC rs777085483, gnomAD rs777085483, REVEL 0.12, MetaLR 0.35
- L18P (p.Leu18Pro), rs2485896909, ClinGen CA370199539, ClinVar RCV002347266, REVEL 0.40, MetaLR 0.42, Uncertain significance, Hereditary cancer-predisposing syndrome
- L18I (p.Leu18Ile), gnomAD 7-152660770-G-T, REVEL 0.14, MetaLR 0.35
- E19K (p.Glu19Lys), rs766826828, ClinGen CA4582410, ClinVar RCV002344886, ClinVar RCV003096805, REVEL 0.14, MetaLR 0.22, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- E19G (p.Glu19Gly), gnomAD 7-152660766-T-C, REVEL 0.14, MetaLR 0.14
- G20D (p.Gly20Asp), rs1369229971, ClinGen CA370199527, ClinVar RCV001217794, ClinVar RCV002356926, REVEL 0.12, MetaLR 0.15, Uncertain significance, XRCC2-related disorder; not provided; Hereditary cancer-predisposing syndrome
- R21del (p.Arg21del), rs756266778, gnomAD 7-152660756-ACTT-, CADD 19.80
- S22I (p.Ser22Ile), rs1016461143, ClinGen CA370199513, ClinVar RCV003377789, AlphaMissense 0.12, MetaLR 0.18, Uncertain significance, Hereditary cancer-predisposing syndrome
- S22N (p.Ser22Asn), rs1016461143, ClinGen CA169488183, ClinVar RCV001025444, ClinVar RCV003558644, REVEL 0.05, AlphaMissense 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- S22R (p.Ser22Arg), rs2485896891, ClinGen CA370199516, ClinVar RCV003377790, REVEL 0.05, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome
- S23F (p.Ser23Phe), gnomAD rs1388202730, REVEL 0.26, MetaLR 0.32
- L24F (p.Leu24Phe), NCI-TCGA Cosmic COSV6377, Ensembl rs1590134314, Likely benign
- L24S (p.Leu24Ser), rs1590134315, ClinGen CA370199501, ClinVar RCV003305386, ClinVar RCV003777120, REVEL 0.41, MetaLR 0.28, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- L24* (p.Leu24Ter), gnomAD 7-152660750-CA-C, CADD 27.80
- L24L (p.Leu24Leu), rs1590134314, gnomAD 7-152660750-C-T, CADD 11.90
- K25E (p.Lys25Glu), rs2116999624, ClinGen CA370199496, ClinVar RCV004521386, Ensembl rs2116999624, REVEL 0.13, MetaLR 0.17, Uncertain significance, Hereditary cancer-predisposing syndrome
- K25K (p.Lys25Lys), gnomAD 7-152660747-T-C, CADD 11.80
- K25* (p.Lys25Ter), gnomAD 7-152660749-T-A, CADD 40.00
- E26* (p.Glu26Ter), NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6377, Variant assessed as somatic; high impact.
- E26K (p.Glu26Lys), Ensembl rs2116999619, Uncertain significance, Hereditary cancer-predisposing syndrome
- E26del (p.Glu26del), gnomAD 7-152660743-TTTC-, CADD 16.90
- E26E (p.Glu26Glu), rs1316556263, gnomAD 7-152660744-T-C, CADD 8.80
- I27M (p.Ile27Met), rs773847550, ClinGen CA4582407, ClinVar RCV003176494, ExAC rs773847550, REVEL 0.05, MetaLR 0.09, Uncertain significance, Hereditary cancer-predisposing syndrome
- I27T (p.Ile27Thr), rs761161980, ClinGen CA4582408, ClinVar RCV001984011, ClinVar RCV002423209, REVEL 0.21, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- I27V (p.Ile27Val), rs1005181554, ClinGen CA169488182, ClinVar RCV001027032, ClinVar RCV001326867, REVEL 0.02, MetaLR 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- E28G (p.Glu28Gly), rs772509446, ClinGen CA4582406, ClinVar RCV004521392, ExAC rs772509446, REVEL 0.23, MetaLR 0.18, Uncertain significance, Hereditary cancer-predisposing syndrome
- E28* (p.Glu28Ter), gnomAD 7-152660740-C-A, CADD 37.00
- P29A (p.Pro29Ala), Ensembl rs2098032742, Uncertain significance
- P29L (p.Pro29Leu), rs2098032740, ClinGen CA370199465, ClinVar RCV001340977, Ensembl rs2098032740, AlphaMissense 0.20, MetaLR 0.31, Uncertain significance, not provided
- P29S (p.Pro29Ser), rs2098032742, ClinGen CA370199468, ClinVar RCV001312321, Ensembl rs2098032742, REVEL 0.17, AlphaMissense 0.22, Uncertain significance, not provided
- P29T (p.Pro29Thr), rs2098032742, ClinGen CA370199470, ClinVar RCV004521393, AlphaMissense 0.22, MetaLR 0.19, Uncertain significance, Hereditary cancer-predisposing syndrome
- P29R (p.Pro29Arg), gnomAD 7-152660736-G-C, REVEL 0.30, MetaLR 0.28
- N30D (p.Asn30Asp), rs2098032739, ClinGen CA370199463, ClinVar RCV003305384, Ensembl rs2098032739, REVEL 0.07, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome
- L31M (p.Leu31Met), rs748198457, ClinGen CA370199456, ClinVar RCV001369291, ExAC rs748198457, AlphaMissense 0.20, MetaLR 0.37, Uncertain significance, not provided
- L31V (p.Leu31Val), rs748198457, ClinGen CA4582405, ClinVar RCV000484446, ClinVar RCV001018997, REVEL 0.23, AlphaMissense 0.20, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- L31L (p.Leu31Leu), gnomAD 7-152660729-C-T, CADD 11.00
- F32I (p.Phe32Ile), Ensembl rs2116999588, MetaLR 0.23, MetaSVM -0.72
- F32L (p.Phe32Leu), rs1554411684, gnomAD 7-152660722-CAGCA, CADD 27.60
- A33P (p.Ala33Pro), rs774296079, ClinGen CA4582404, ClinVar RCV000460519, ClinVar RCV001019768, REVEL 0.29, AlphaMissense 0.08, Uncertain significance, Fanconi anemia complementation group U; not provided; Hereditary cancer-predispo
- A33S (p.Ala33Ser), ExAC rs774296079, TOPMed rs774296079, gnomAD rs774296079, Uncertain significance, Hereditary cancer-predisposing syndrome
- A33T (p.Ala33Thr), rs774296079, ClinGen CA370199444, ClinVar RCV002387234, ClinVar RCV003103619, AlphaMissense 0.08, MetaLR 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- A33V (p.Ala33Val), rs1392976414, ClinGen CA370199442, ClinVar RCV004521394, gnomAD rs1392976414, REVEL 0.04, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome
- D34N (p.Asp34Asn), rs1563030168, ClinGen CA370199439, ClinVar RCV004521348, TOPMed rs1563030168, REVEL 0.04, MetaLR 0.14, Uncertain significance, Hereditary cancer-predisposing syndrome
- D34V (p.Asp34Val), ExAC rs768885888, gnomAD rs768885888, REVEL 0.13, MetaLR 0.16
- D34D (p.Asp34Asp), rs1454417236, gnomAD 7-152660720-A-G, CADD 10.60
- E35D (p.Glu35Asp), rs2485896782, ClinGen CA370199425, ClinVar RCV002401758, Uncertain significance, Hereditary cancer-predisposing syndrome
- E35K (p.Glu35Lys), Ensembl rs2116999551
- E35E (p.Glu35Glu), gnomAD 7-152660717-T-C, CADD 13.60
- E35G (p.Glu35Gly), gnomAD 7-152660718-T-C, REVEL 0.14, MetaLR 0.16
- D36E (p.Asp36Glu), rs1590134276, ClinGen CA370199418, ClinVar RCV004521349, Uncertain significance, Hereditary cancer-predisposing syndrome
- D36N (p.Asp36Asn), rs749538198, ClinGen CA4582402, ClinVar RCV000479449, ClinVar RCV001017195, REVEL 0.07, MetaLR 0.11, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- D36V (p.Asp36Val), rs2098032724, ClinGen CA370199420, ClinVar RCV002424222, ClinVar RCV003101055, AlphaMissense 0.10, MetaLR 0.08, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- D36G (p.Asp36Gly), gnomAD 7-152660715-T-C, REVEL 0.07, MetaLR 0.04
- S37L (p.Ser37Leu), Ensembl rs2116999532, REVEL 0.13, MetaLR 0.14
- S37F (p.Ser37Phe), rs1213272601, gnomAD 7-152660712-G-GA, CADD 28.20
- P38A (p.Pro38Ala), rs2485896765, ClinGen CA370199410, ClinVar RCV002320504, REVEL 0.13, MetaLR 0.17, Uncertain significance, Hereditary cancer-predisposing syndrome
- P38L (p.Pro38Leu), rs2485896764, ClinGen CA370199406, ClinVar RCV003165248, REVEL 0.19, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome
- P38S (p.Pro38Ser), rs2485896765, ClinGen CA370199409, ClinVar RCV002320532, REVEL 0.08, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome
- P38R (p.Pro38Arg), gnomAD 7-152660709-G-C, REVEL 0.22, MetaLR 0.23
- V39A (p.Val39Ala), rs757019795, ClinGen CA4582401, ClinVar RCV002330054, ClinVar RCV003094617, REVEL 0.11, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- V39M (p.Val39Met), rs730882040, ClinGen CA300465, ClinVar RCV000161103, ClinVar RCV000791369, REVEL 0.08, MetaLR 0.20, Conflicting interpretations, Hereditary cancer-predisposing syndrome; not provided; not specified
- V39V (p.Val39Val), rs200974031, gnomAD 7-152660705-C-G, CADD 5.57
- V39G (p.Val39Gly), gnomAD 7-152660706-A-C, REVEL 0.10, MetaLR 0.12
- H40P (p.His40Pro), rs777753452, ClinGen CA370199398, ClinVar RCV001215750, ClinVar RCV003163655, REVEL 0.30, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- H40Q (p.His40Gln), rs1306014974, ClinGen CA370199395, ClinVar RCV001911616, ClinVar RCV002359386, REVEL 0.05, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- H40R (p.His40Arg), rs777753452, ClinGen CA4582399, ClinVar RCV000484587, ClinVar RCV002350055, REVEL 0.05, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome; XRCC2-related disorder; not provided
- H40N (p.His40Asn), gnomAD 7-152660704-G-T, REVEL 0.08, MetaLR 0.20
- H40Y (p.His40Tyr), gnomAD 7-152660704-G-A, REVEL 0.10, MetaLR 0.28
- G41D (p.Gly41Asp), rs1590129831, ClinGen CA370199380, ClinVar RCV001010449, ClinVar RCV001860637, AlphaMissense 0.61, MetaLR 0.70, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- G41S (p.Gly41Ser), Ensembl rs2116999505, REVEL 0.77, MetaLR 0.64
- G41V (p.Gly41Val), rs1590129831, ClinGen CA370199378, ClinVar RCV001058507, ClinVar RCV002365723, AlphaMissense 0.61, MetaLR 0.70, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- G41A (p.Gly41Ala), gnomAD 7-152649363-C-G, REVEL 0.78, MetaLR 0.70
- D42E (p.Asp42Glu), rs1435337206, ClinGen CA370199371, ClinVar RCV001362504, ClinVar RCV002377517, REVEL 0.08, MetaLR 0.12, Uncertain significance, Hereditary cancer-predisposing syndrome
- D42N (p.Asp42Asn), rs763065363, ClinGen CA4582383, ClinVar RCV002400748, ExAC rs763065363, REVEL 0.08, MetaLR 0.22, Uncertain significance, Hereditary cancer-predisposing syndrome
- D42G (p.Asp42Gly), gnomAD 7-152649360-T-C, REVEL 0.21, MetaLR 0.19
- D42Y (p.Asp42Tyr), gnomAD 7-152649361-C-A, REVEL 0.47, MetaLR 0.45
- I43N (p.Ile43Asn), rs1324568176, ClinGen CA370199367, ClinVar RCV000732072, ClinVar RCV002386303, REVEL 0.41, AlphaMissense 0.66, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- I43S (p.Ile43Ser), rs1324568176, ClinGen CA370199365, ClinVar RCV004521351, AlphaMissense 0.66, MetaLR 0.36, Uncertain significance, Hereditary cancer-predisposing syndrome
- I43V (p.Ile43Val), rs2485882201, ClinGen CA370199369, ClinVar RCV002374328, REVEL 0.06, MetaLR 0.06, Likely benign, Hereditary cancer-predisposing syndrome
- L44I (p.Leu44Ile), NCI-TCGA Cosmic COSV1008, REVEL 0.04, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- L44V (p.Leu44Val), rs2485882194, ClinGen CA370199363, ClinVar RCV003840082, ClinVar RCV004366903, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- E45A (p.Glu45Ala), rs2485882191, ClinGen CA370199354, ClinVar RCV002387903, Uncertain significance, Hereditary cancer-predisposing syndrome
- E45Q (p.Glu45Gln), gnomAD 7-152649352-C-G, REVEL 0.48, MetaLR 0.42
- F46I (p.Phe46Ile), gnomAD 7-152649349-A-T, REVEL 0.22, MetaLR 0.09
- H47Q (p.His47Gln), Ensembl rs2098027538, REVEL 0.17, MetaLR 0.08
- H47R (p.His47Arg), rs587780126, ClinGen CA288126, ClinVar RCV000115886, ClinVar RCV001194892, REVEL 0.16, MetaLR 0.15, Uncertain significance, Hereditary cancer-predisposing syndrome; not specified; not provided
- G48D (p.Gly48Asp), rs2098027535, ClinGen CA370199329, ClinVar RCV001236413, Ensembl rs2098027535, AlphaMissense 0.99, MetaLR 0.84, Uncertain significance, not provided
- G48S (p.Gly48Ser), rs1590129815, ClinGen CA370199334, ClinVar RCV001011542, Ensembl rs1590129815, REVEL 0.90, MetaLR 0.76, Uncertain significance, Hereditary cancer-predisposing syndrome
- G48G (p.Gly48Gly), rs369819565, gnomAD 7-152649341-G-T, CADD 9.10, SIFT 0.00
- G48V (p.Gly48Val), gnomAD 7-152649342-C-A, REVEL 0.85, MetaLR 0.84
- P49T (p.Pro49Thr), Ensembl rs2116988477
- P49P (p.Pro49Pro), rs770063304, gnomAD 7-152649338-T-C, CADD 9.96, SIFT 1.00
- E50D (p.Glu50Asp), ExAC rs746751990, TOPMed rs746751990, gnomAD rs746751990, REVEL 0.17, MetaLR 0.19, Uncertain significance, Hereditary cancer-predisposing syndrome
- E50Q (p.Glu50Gln), Ensembl rs2116988468
- E50* (p.Glu50Ter), gnomAD 7-152649337-C-A, CADD 37.00, SIFT 0.03
- G51E (p.Gly51Glu), rs1590129803, ClinGen CA370199312, ClinVar RCV000815479, ClinVar RCV002397693, REVEL 0.74, MetaLR 0.69, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- G51R (p.Gly51Arg), rs2116988454, ClinGen CA370199315, ClinVar RCV002392396, Ensembl rs2116988454, AlphaMissense 0.87, MetaLR 0.49, Uncertain significance, Hereditary cancer-predisposing syndrome
- T52A (p.Thr52Ala), rs2485882120, ClinGen CA370199308, NCI-TCGA Cosmic COSV1008, ClinVar RCV003832198, REVEL 0.18, MetaLR 0.23, Uncertain significance, not provided
- T52I (p.Thr52Ile), 1000Genomes rs530663304, ExAC rs530663304, gnomAD rs530663304, REVEL 0.41, MetaLR 0.41, Uncertain significance
- T52K (p.Thr52Lys), rs530663304, ClinGen CA4582378, ClinVar RCV001820452, ClinVar RCV002397762, REVEL 0.45, MetaLR 0.53, Uncertain significance, not specified; Hereditary cancer-predisposing syndrome
- T52R (p.Thr52Arg), 1000Genomes rs530663304, ExAC rs530663304, gnomAD rs530663304, MetaLR 0.53, MetaSVM 0.17, Uncertain significance, Hereditary cancer-predisposing syndrome
- G53A (p.Gly53Ala), rs1163807963, ClinGen CA16622036, ClinVar RCV002398405, gnomAD rs1163807963, REVEL 0.94, AlphaMissense 0.65, Uncertain significance, Hereditary cancer-predisposing syndrome
- G53E (p.Gly53Glu), rs1163807963, ClinGen CA370199302, ClinVar RCV002653459, gnomAD rs1163807963, AlphaMissense 0.65, MetaLR 0.94, Uncertain significance, not provided
- G53R (p.Gly53Arg), Ensembl rs2116988435, SIFT 0.00
- K54E (p.Lys54Glu), rs2116988427, ClinGen CA370199299, ClinVar RCV001985939, ClinVar RCV003170344, AlphaMissense 0.97, MetaLR 0.90, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- K54N (p.Lys54Asn), gnomAD rs1473933943, REVEL 0.81, MetaLR 0.87, Uncertain significance, Hereditary cancer-predisposing syndrome
- T55A (p.Thr55Ala), rs2485882094, ClinGen CA370199291, ClinVar RCV004521353, Uncertain significance, Hereditary cancer-predisposing syndrome
- E56D (p.Glu56Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E56Q (p.Glu56Gln), Ensembl rs2116988418
- M57I (p.Met57Ile), Ensembl rs2116988407, REVEL 0.12, MetaLR 0.19
- M57V (p.Met57Val), gnomAD rs2098027527, REVEL 0.18, MetaLR 0.26
- M57T (p.Met57Thr), gnomAD 7-152649315-A-G, REVEL 0.40, MetaLR 0.21
- L58F (p.Leu58Phe), rs1030204779, ClinGen CA370199268, ClinVar RCV004521354, AlphaMissense 0.16, MetaLR 0.24, Uncertain significance, Hereditary cancer-predisposing syndrome
- L58I (p.Leu58Ile), rs1030204779, ClinGen CA169486958, ClinVar RCV002407403, ClinVar RCV005097711, REVEL 0.20, AlphaMissense 0.16, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
- Y59C (p.Tyr59Cys), rs1590129796, ClinGen CA370199260, ClinVar RCV001013087, ClinVar RCV001860735, REVEL 0.13, AlphaMissense 0.13, Uncertain significance, not provided; Hereditary cancer-predisposing syndrome
- Y59S (p.Tyr59Ser), rs1590129796, ClinGen CA370199259, ClinVar RCV003176559, AlphaMissense 0.13, MetaLR 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome
- Y59Y (p.Tyr59Tyr), rs1554410569, gnomAD 7-152649308-A-G, CADD 8.60, SIFT 0.00
- Y59H (p.Tyr59His), gnomAD 7-152649310-A-G, REVEL 0.31, MetaLR 0.09
- H60Y (p.His60Tyr), rs1554410567, ClinGen CA370199254, ClinVar RCV000570344, ClinVar RCV006463409, REVEL 0.33, MetaLR 0.16, Uncertain significance, Hereditary cancer-predisposing syndrome; not provided
Public XRCC2 analysis runs
- XRCC2 analysis run — XRCC2 (818 variants) — completed 2026-08-20